Literature DB >> 20397967

P-glycoprotein related drug interactions: clinical importance and a consideration of disease states.

Caroline A Lee1, Jack A Cook, Eric L Reyner, Dennis A Smith.   

Abstract

IMPORTANCE OF THE FIELD: P-glycoprotein (P-gp) is the most characterized drug transporter in terms of its clinical relevance for pharmacokinetic disposition and interaction with other medicines. Clinically significant P-gp related drug interactions appear restricted to digoxin. P-gp may act as a major barrier to current and effective drug treatment in a number of diseases including cancer, AIDS, Alzheimer's and epilepsy due to its expression in tumors, lymphocytes, cell membranes of brain capillaries and the choroid plexus. AREAS COVERED IN THIS REVIEW: This review summarizes the current understanding of P-gp structure/function, clinical importance of P-gp related drug interactions and the modulatory role this transporter may contribute towards drug efficacy in disease states such as cancer, AIDS, Alzheimer's and epilepsy. WHAT THE READER WILL GAIN: The reader will gain an understanding that the clinical relevance of P-gp in drug interactions is limited. In certain disease states, P-gp in barrier tissues can modulate changes in regional distribution. TAKE HOME MESSAGE: P-gp inhibition in isolation will not result in clinically important alterations in systemic exposure; however, P-gp transport may be of significance in barrier tissues (tumors, lymphocytes, brain) resulting in attenuated efficacy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20397967     DOI: 10.1517/17425251003610640

Source DB:  PubMed          Journal:  Expert Opin Drug Metab Toxicol        ISSN: 1742-5255            Impact factor:   4.481


  20 in total

Review 1.  The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery.

Authors:  Dennis A Smith; Li Di; Edward H Kerns
Journal:  Nat Rev Drug Discov       Date:  2010-12       Impact factor: 84.694

2.  Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin.

Authors:  Lot A Devriese; Petronella Els O Witteveen; Jantien Wanders; Kenneth Law; Geoff Edwards; Larisa Reyderman; William Copalu; Fuping Peng; Serena Marchetti; Jos H Beijnen; Alwin D R Huitema; Emile E Voest; Jan H M Schellens
Journal:  Br J Clin Pharmacol       Date:  2013-02       Impact factor: 4.335

3.  Induction of P-glycoprotein by antiretroviral drugs in human brain microvessel endothelial cells.

Authors:  Gary N Y Chan; Rucha Patel; Carolyn L Cummins; Reina Bendayan
Journal:  Antimicrob Agents Chemother       Date:  2013-07-08       Impact factor: 5.191

4.  Structures of P-glycoprotein reveal its conformational flexibility and an epitope on the nucleotide-binding domain.

Authors:  Andrew B Ward; Paul Szewczyk; Vinciane Grimard; Chang-Wook Lee; Lorena Martinez; Rupak Doshi; Alexandra Caya; Mark Villaluz; Els Pardon; Cristina Cregger; Douglas J Swartz; Pierre Guy Falson; Ina L Urbatsch; Cedric Govaerts; Jan Steyaert; Geoffrey Chang
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-30       Impact factor: 11.205

5.  Multiple Drug Transport Pathways through Human P-Glycoprotein.

Authors:  James W McCormick; Pia D Vogel; John G Wise
Journal:  Biochemistry       Date:  2015-07-10       Impact factor: 3.162

6.  Induction of expression and functional activity of P-glycoprotein efflux transporter by bioactive plant natural products.

Authors:  Alaa H Abuznait; Hisham Qosa; Nicholas D O'Connell; Jessica Akbarian-Tefaghi; Paul W Sylvester; Khalid A El Sayed; Amal Kaddoumi
Journal:  Food Chem Toxicol       Date:  2011-08-10       Impact factor: 6.023

7.  Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole.

Authors:  L A Devriese; M Mergui-Roelvink; J Wanders; A Jenner; G Edwards; L Reyderman; W Copalu; F Peng; S Marchetti; J H Beijnen; J H M Schellens
Journal:  Invest New Drugs       Date:  2012-05-05       Impact factor: 3.850

8.  Assessment of P-glycoprotein activity in the Blood-Brain Barrier (BBB) using Near Infrared Fluorescence (NIRF) imaging techniques.

Authors:  Ngoc H On; Fang Chen; Martha Hinton; Donald W Miller
Journal:  Pharm Res       Date:  2011-05-20       Impact factor: 4.200

9.  Effect of type 2 diabetes on Gd-EOB-DTPA uptake into liver parenchyma: replication study in human subjects.

Authors:  Soma Kumasaka; Yuko Seki; Yuka Kumasaka; Yoshito Tsushima
Journal:  Abdom Radiol (NY)       Date:  2021-06-23

10.  Conformational changes in the nucleotide-binding domains of P-glycoprotein induced by ATP hydrolysis.

Authors:  Sepehr Dehghani-Ghahnaviyeh; Karan Kapoor; Emad Tajkhorshid
Journal:  FEBS Lett       Date:  2020-12-10       Impact factor: 4.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.